Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1600txm

PASSWORD:
 * * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'REGISTRY' AT 17:06:48 ON 21 JUN 2008
FILE 'REGISTRY' ENTERED AT 17:06:48 ON 21 JUN 2008

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	1.38	224.51

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-6.40

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	1.38	224.51

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-6.40

FILE 'REGISTRY' ENTERED AT 17:06:57 ON 21 JUN 2008

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 20 JUN 2008 HIGHEST RN 1029712-63-7
DICTIONARY FILE UPDATES: 20 JUN 2008 HIGHEST RN 1029712-63-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10566585.str

L5   STRUCTURE UPLOADED

=> s l5
SAMPLE SEARCH INITIATED 17:07:21 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -   1130 TO ITERATE

100.0% PROCESSED   1130 ITERATIONS   1 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS: 20584 TO   24616

McIntosh

PROJECTED ANSWERS: 1 TO 80

L6 1 SEA SSS SAM L5

=> s l5 full
FULL SEARCH INITIATED 17:07:27 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 22707 TO ITERATE

100.0% PROCESSED 22707 ITERATIONS 22 ANSWERS
SEARCH TIME: 00.00.01

L7 22 SEA SSS FUL L5

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 178.36 402.87

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE ENTRY TOTAL SESSION
CA SUBSCRIBER PRICE 0.00 -6.40

FILE 'CAPLUS' ENTERED AT 17:07:33 ON 21 JUN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 21 Jun 2008 VOL 148 ISS 26
FILE LAST UPDATED: 20 Jun 2008 (20080620/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> s l7
L8 14 L7

=> d bib abs hitstr 1-14 l8

L8 ANSWER 1 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2006:912445 CAPLUS
DN 145:285165
TI Pharmaceutical compositions containing N-glucoside compounds
IN Nomura, Sumihiro; Sakamoto, Toshiaki; Ueda, Kiichiro
PA Tanabe Seiyaku Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 30pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 2006232825	A	20060907	JP 2006-19935	20060130
PRAI JP 2005-23727	A	20050131		

OS MARPAT 145:285165
GI



I

AB The invention relates to a pharmaceutical composition characterized by containing a compound I (ring A and B are (un)substituted monocycle unsatd. hetero rings, etc.; R = H, lower alkyl, lower alkonoyl, lower alkoxycarbonyl) or its salt or prodrug as an active component, suitable for use for treatment and/or prevention of diabetes or obesity. For example, 2-(4-ethylbenzyl)-N-(β-D-glucopyranosyl)aniline was prepared, and examined for its inhibitory effect on SGLT 2 (sodium-dependent glucose transporter 2) in vitro.

IT 841236-78-0P 841236-79-1P 841236-80-4P
841236-81-5P 841236-82-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(pharmaceutical compns. containing N-glucoside compds. for treatment of diabetes, obesity, and related diseases)

RN 841236-78-0 CAPLUS

CN β-D-Glucopyranosylamine, N-[2-[(4-ethylphenyl)methyl]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 841236-79-1 CAPLUS

CN β-D-Glucopyranosylamine, N-[2-[(4-ethylphenyl)methyl]-4-(trifluoromethyl)phenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 841236-80-4 CAPLUS
CN β-D-Glucopyranosylamine, N-[2-(phenylmethyl)phenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 841236-81-5 CAPLUS
CN β-D-Glucopyranosylamine, N-[2-[(4-ethylphenyl)methyl]-4-fluorophenyl]-
(CA INDEX NAME)

Absolute stereochemistry.



RN 841236-82-6 CAPLUS
CN β-D-Glucopyranosylamine, N-[2-[(4-ethylphenyl)methyl]-3,4-
difluorophenyl]- (CA INDEX NAME)

Absolute stereochemistry.



L8 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2006:620496 CAPLUS
DN 146:402193
TI Synthesis and hydrolysis of N,N'-di-D-glucopyranosyldiaminodiphenylmethane
AU Yang, Deming; Fang, Zhijie
CS School of Chemical Engineering, Nanjing University of Science +
Technology, Nanjing, 210094, Peop. Rep. China
SO Huaxue Yanjiu Yu Yingyong (2005), 17(3), 414-416
CODEN: HYYIFM; ISSN: 1004-1656
PB Huaxue Yanjiu Yu Yingyong Bianjibu

DT Journal
LA Chinese
OS CASREACT 146:402193
AB N,N'-Di-D-glucopyranosyldiaminodiphenylmethane [i.e., N,N'-[(methylene)di-4,1-phenylene]-D-glucopyranosylamine] was prepared by the condensation reaction of D-glucose with 4,4'-diaminodiphenylmethane (at a molar ratio of 1:1) in anhydrous methanol under reflux for 25 h in a yield of 53.3% and purity of 99.4%. Its structure was characterized by elemental anal., IR, and NMR spectroscopy. The research of the hydrolysis of the product showed the condensation reaction was at equilibrium The influence of time and the 4,4'-diaminodiphenylmethane concentration in water on the hydrolysis was also researched.
IT 30796-64-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of N,N'-[(methylene)phenylene]-D-glucopyranosylamine and study of its hydrolysis reaction)
RN 30796-64-6 CAPLUS
CN D-Glucopyranosylamine, N,N'-(methylenedi-4,1-phenylene)bis- (CA INDEX NAME)

Absolute stereochemistry.



L8 ANSWER 3 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:120945 CAPLUS
DN 142:219494
TI Preparation of aryl-aminodeoxy monosaccharides as antidiabetic agents
IN Nomura, Sumihiro; Sakamoto, Toshiaki; Ueta, Kiichiro
PA Tanabe Seiyaku Co., Ltd., Japan
SO PCT Int. Appl., 62 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 8

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005012321	A1	20050210	WO 2004-JP11311	20040730
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004260760	A1	20050210	AU 2004-260760	20040730
CA 2534022	A1	20050210	CA 2004-2534022	20040730
EP 1654269	A1	20060510	EP 2004-771313	20040730
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
CN 1829728	A	20060906	CN 2004-80022006	20040730
BR 2004013233	A	20061003	BR 2004-13233	20040730
JP 2007518682	T	20070712	JP 2006-519250	20040730
NO 2006000219	A	20060428	NO 2006-219	20060116
MX 2006PA01273	A	20060411	MX 2006-PA1273	20060131
IN 2006CN00725	A	20070629	IN 2006-CN725	20060228
US 20060217323	A1	20060928	US 2006-446014	20060602

	US 20060229260	A1	20061012	US 2006-453728	20060615
	US 20060234954	A1	20061019	US 2006-453727	20060615
	US 20060293251	A1	20061228	US 2006-453726	20060615
	US 20070060545	A1	20070315	US 2006-566585	20060728
	AU 2008200240	A1	20080207	AU 2008-200240	20080117
PRAI	US 2003-491523P	P	20030801		
	US 2003-491534P	P	20030801		
	US 2003-519155P	P	20031112		
	US 2003-519209P	P	20031112		
	US 2003-519210P	P	20031112		
	US 2003-519381P	P	20031112		
	US 2004-579722P	P	20040615		
	US 2004-579730P	P	20040615		
	US 2004-579758P	P	20040615		
	US 2004-579792P	P	20040615		
	AU 2004-260761	A3	20040730		
	US 2004-903034	A3	20040730		
	US 2004-903136	A3	20040730		
	US 2004-903233	A3	20040730		
	US 2004-903234	A3	20040730		
	WO 2004-JP11311	W	20040730		

OS CASREACT 142:219494; MARPAT 142:219494

GI



I II

AB Aryl-aminodeoxy monosaccharides I, wherein A and B are (1) A is an optionally substituted unsatd. monocyclic heterocyclic , and B is an optionally substituted unsatd. monocyclic heterocyclic , an optionally substituted unsatd. fused hetero-bicyclic , or an optionally substituted benzene , (2) A is an optionally substituted benzene , and B is an optionally substituted unsatd. monocyclic heterocyclic , an optionally substituted unsatd. fused hetero-bicyclic , or an optionally substituted benzene , or (3) A is an optionally substituted unsatd. fused hetero-bicyclic , wherein -NR- group and -CH2- group are both on the same of the unsatd. fused hetero-bicyclic , and B is an optionally substituted monocyclic unsatd. heterocyclic , an optionally substituted unsatd. fused hetero-bicyclic , or an optionally substituted benzene ; and R is a hydrogen atom, a lower alkyl group, a lower alkanoyl group or a lower alkoxycarbonyl group, or a pharmaceutically acceptable salt thereof, or a prodrug thereof. A method is claimed for treatment of type 1 and 2 diabetes mellitus, which comprises administering to a mammalian species in need of treatment a therapeutically effective amount of the compound, or in combination with another antidiabetic agent, an agent for treating diabetic complications, an anti-obesity agent, an antihypertensive agent, an antiplatelet agent, an anti-atherosclerotic agent and/or a hypolipidemic agent. Thus, title II was prepared and tested as an antidiabetic agent. The dosage of the present compd.s or a pharmaceutically acceptable salt thereof may vary according to the administration routes, ages, body weight, conditions of a patient, or kinds and severity of a disease to be treated, and it is usually in the range of about 0.1 to 50 mg/kg/day, preferably in the range of about 0.1 to 30 mg/kg/day.

IT 841236-78-0P 841236-79-1P 841236-80-4P
841236-81-5P 841236-82-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of aryl-aminodeoxy monosaccharides as antidiabetic agents)

RN 841236-78-0 CAPLUS

CN β-D-Glucopyranosylamine, N-[2-[(4-ethylphenyl)methyl]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 841236-79-1 CAPLUS
CN β-D-Glucopyranosylamine, N-[2-[(4-ethylphenyl)methyl]-4-(trifluoromethyl)phenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 841236-80-4 CAPLUS
CN β-D-Glucopyranosylamine, N-[2-(phenylmethyl)phenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 841236-81-5 CAPLUS
CN β-D-Glucopyranosylamine, N-[2-[(4-ethylphenyl)methyl]-4-fluorophenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 841236-82-6 CAPLUS
CN β-D-Glucopyranosylamine, N-[2-[(4-ethylphenyl)methyl]-3,4-difluorophenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 4 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2003:521351 CAPLUS
DN 139:239669
TI Synthesis and activity of novel benzoxazole derivatives of mannopeptimycin glycopeptide antibiotics
AU Sum, Phaik-Eng; How, David; Torres, Nancy; Newman, Howard; Petersen, Peter J.; Mansour, Tarek S.
CS Chemical Sciences, Wyeth Research, Pearl River, NY, 10965, USA
SO Bioorganic & Medicinal Chemistry Letters (2003), 13(15), 2607-2610
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Science B.V.
DT Journal
LA English
OS CASREACT 139:239669
AB A series of benzoxazole derivs. of the mannopeptimycin glycopeptide antibiotics was synthesized via a novel benzoxazole formation reaction by treating aminophenol of mannopeptimycin-β with an aldehyde and DDQ in DMF. Some of these derivs. showed good activity against Gram-(+) bacteria when compared to the parent compound mannopeptimycin-β.
IT 596818-67-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(synthesis and activity of novel benzoxazole derivs. of mannopeptimycin glycopeptide antibiotics)
RN 596818-67-6 CAPLUS
CN Cyclo[3-[2-[(2,3,4,6-tetra-O-benzoyl-β-D-glucopyranosyl)amino]-5-benzoxazolyl]-D-alanyl-(3S)-3-[(4S)-2-amino-4,5-dihydro-1H-imidazol-4-yl]-L-seryl-(3R)-3-[(5S)-2-amino-4,5-dihydro-1-α-D-mannopyranosyl-1H-imidazol-5-yl]-D-seryl-L-serylglycyl-(βS)-β-methyl-L-phenylalanyl] (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2003:137713 CAPLUS
DN 139:7095
TI Syntheses of guanidinoglycosides with the inventive use of Mitsunobu conditions and 1,8-diazabicyclo[5.4.0]undec-7-ene
AU Lin, Peishan; Heng, Sabrina Cher Hui; Sim, Mui Mui
CS Institute of Molecular and Cell Biology, Singapore, 117609, Singapore
SO Synthesis (2003), (2), 255-261
CODEN: SYNTBF; ISSN: 0039-7881
PB Georg Thieme Verlag
DT Journal
LA English
OS CASREACT 139:7095
AB A series of novel guanidinoglycosides was successfully synthesized. This was accomplished with the use of Mitsunobu conditions as a strategy to convert the glycopyranose anomeric hydroxy group to give the corresponding substituted masked guanidines in high yields. Subsequent deprotection and coupling with Fmoc protected β-amino acid, afforded a series of N,N'-substituted-methylisothioureas. Cleavage of Fmoc followed by concomitant cyclization was achieved with a catalytic amount of DBU to give the guanidinoglycosides.
IT 535952-67-1P 535952-69-3P 535952-71-7P
RL: SPN (Synthetic preparation); PREP (Preparation)

(syntheses of guanidinoglycosides with inventive use of Mitsunobu conditions and diazabicycloundecene)

RN 535952-67-1 CAPLUS
CN 4(1H)-Pyrimidinone, 5,6-dihydro-6-[(4-methylphenyl)methyl]-2-[(2,3,4,6-tetra-O-acetyl-α-D-galactopyranosyl)amino]-, (6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535952-69-3 CAPLUS
CN 4(1H)-Pyrimidinone, 5,6-dihydro-6-[(4-methylphenyl)methyl]-2-[(2,3,4,6-tetra-O-acetyl-α-D-glucopyranosyl)amino]-, (6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 535952-71-7 CAPLUS
CN 4(1H)-Pyrimidinone, 5,6-dihydro-6-[(4-nitrophenyl)methyl]-2-[(2,3,4,6-tetra-O-acetyl-α-D-glucopyranosyl)amino]-, (6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2002:832983 CAPLUS
DN 137:336791
TI Preparation of glycopeptide antibiotics
IN Abbanat, Darren Robert; Bailey, Arthur Emery; Bernan, Valerie Sue; Greenstein, Michael; Lotvin, Jason Arnold; Ruppen, Mark Edward; Sutherland, Alan Gordon; He, Haiyin
PA American Cyanamid Company, USA
SO PCT Int. Appl., 515 pp.
CODEN: PIXXD2
DT Patent

LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002086141	A1	20021031	WO 2002-US13108	20020425
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2445216	A1	20021031	CA 2002-2445216	20020425
	AU 2002307567	A1	20021105	AU 2002-307567	20020425
	US 20030054508	A1	20030320	US 2002-132012	20020425
	US 6713448	B2	20040330		
	US 20030087812	A1	20030508	US 2002-131890	20020425
	US 6914045	B2	20050705		
	US 20030092610	A1	20030515	US 2002-131847	20020425
	US 6964860	B2	20051115		
	EP 1390521	A1	20040225	EP 2002-764346	20020425
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	MX 2003PA09803	A	20040129	MX 2003-PA9803	20031024
	US 20040158035	A1	20040812	US 2004-771652	20040204
	US 7183253	B2	20070227		
	US 20050288221	A1	20051229	US 2005-116149	20050427
PRAI	US 2001-286396P	P	20010425		
	US 2001-286244P	P	20010425		
	US 2001-286249P	P	20010425		
	US 2002-131847	A3	20020425		
	US 2002-132012	A3	20020425		
	WO 2002-US13108	W	20020425		

OS MARPAT 137:336791

AB The invention provides glycopeptide antibiotics and their derivs. prepared by fermentation of Streptomyces hygroscopicus strains and modified by organic transformation, biochem. transformation and biotransformation. These compds. are useful as antibiotic agents against gram pos. and neg. bacteria.

IT 474326-34-6P
RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of glycopeptide antibiotics)

RN 474326-34-6 CAPLUS

CN Cyclo[3-[2-[(2,3,4,6-tetra-O-benzoylhexopyranosyl)amino]-5-benzoxazolyl]alanyl-3-(2-amino-4,5-dihydro-1H-imidazol-4-yl)seryl-3-(2-amino-1-hexopyranosyl-4,5-dihydro-1H-imidazol-5-yl)serylserylglycyl-β-methylphenylalanyl] (9CI) (CA INDEX NAME)

PAGE 1-A



— Ph

— Ph

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 7 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2002:832574 CAPLUS
DN 137:338136
TI Preparation of glycopeptide antibiotics
IN Abbanat, Darren Robert; Bernan, Valerie Sue; Dushin, Russell George; Greenstein, Michael; He, Haiyin; Lang, Stanley Albert; Newman, Howard; Sakya, Subas; Sum, Phaik-Eng; Sutherland, Alan Gordon; Wang, Ting-Zhong; Ruppen, Mark Edward; Bailey, Arthur Emery; Chi, Ping; Shen, Bo; Kong, Fangming; Lotvin, Jason Arnold
PA American Cyanamid Company, USA
SO PCT Int. Appl., 548 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002085307	A2	20021031	WO 2002-US13120	20020425
	WO 2002085307	A3	20030925		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2444673	A1	20021031	CA 2002-2444673	20020425
	AU 2002303480	A1	20021105	AU 2002-303480	20020425
	US 20030054508	A1	20030320	US 2002-132012	20020425
	US 6713448	B2	20040330		
	US 20030087812	A1	20030508	US 2002-131890	20020425
	US 6914045	B2	20050705		
	US 20030092610	A1	20030515	US 2002-131847	20020425
	US 6964860	B2	20051115		
	EP 1390056	A2	20040225	EP 2002-731505	20020425
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	MX 2003PA09802	A	20050307	MX 2003-PA9802	20031024
	US 20040158035	A1	20040812	US 2004-771652	20040204
	US 7183253	B2	20070227		
	US 20050288221	A1	20051229	US 2005-116149	20050427
PRAI	US 2001-286244P	P	20010425		
	US 2001-286249P	P	20010425		
	US 2001-286396P	P	20010425		
	US 2002-131847	A3	20020425		
	US 2002-132012	A3	20020425		
	WO 2002-US13120	W	20020425		

OS MARPAT 137:338136
GI



I

AB Glycopeptide antibiotics I [R1 = 1-phenylethyl, 1-(halophenyl)ethyl, benzyl, 1-(2-thienyl)ethyl, 1-cyclohexylethyl, cyclohexylmethyl, phenyl; R2 = CH2C6H2R2b(OR2a)R2c-3,4,5 (R2a, R2b, R2c = H, (cyclo)alkyl, etc.), 4-R2aO-substituted cyclohexylmethyl, cyclohexylmethyl, 2-substituted 5-benzoxazolyl or 5-benzofuranyl; R3, R4 = H, OH, a silyl or acyl group; R5, R6a-R6e = H, (cyclo)alkyl, alkenyl, alkynyl, acyl, 2- or 4-nitrophenyl, certain heterocyclic groups; R7 = H, (cyclo)alkyl, alkenyl, alkynyl, a silyl or acyl group (with provisos)] or their pharmaceutically-acceptable salts were prepared and assayed for biol. activity. Thus, cyclo[3-cyclohexyl-2-aminobutanoyl-O-(4-O-hexopyranosylhexopyranosyl)tyrosyl-3-(2-iminoimidazolidin-4-yl)seryl-3-(3-hexopyranosyl-2-iminoimidazolidin-4-yl)serylserylglycyl] (claimed compound) was prepared and showed MIC = 32 and 4 μg/mL for inhibition of Staphylococcus aureus (GC 1131) and Coagulase Neg. Staphylococcus (GC 4549), resp.

IT 474326-34-6P
RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of glycopeptide antibiotics)

RN 474326-34-6 CAPLUS

CN Cyclo[3-[2-[(2,3,4,6-tetra-O-benzoylhexopyranosyl)amino]-5-benzoxazolyl]alanyl-3-(2-amino-4,5-dihydro-1H-imidazol-4-yl)seryl-3-(2-amino-1-hexopyranosyl-4,5-dihydro-1H-imidazol-5-yl)serylserylglycyl-β-methylphenylalanyl] (9CI) (CA INDEX NAME)

PAGE 1-A



— Ph

— Ph

L8 ANSWER 8 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2002:259510 CAPLUS
DN 137:20536
TI Total Synthesis of Spicamycin
AU Suzuki, Tamotsu; Suzuki, Sayaka T.; Yamada, Iwao; Koashi, Yoshiaki; Yamada, Kazue; Chida, Noritaka
CS Department of Applied Chemistry Faculty of Science and Technology, Keio University, Hiyoshi, Kohoku-ku, Yokohama, 223-8522, Japan
SO Journal of Organic Chemistry (2002), 67(9), 2874-2880
CODEN: JOCEAH; ISSN: 0022-3263
PB American Chemical Society
DT Journal
LA English
OS CASREACT 137:20536
GI



I

AB The first total synthesis of one of the spicamycin congeners, SPM VIII I, is described. A preliminary model study for construction of the characteristic N-glycoside linkage in spicamycin using tetra-O-benzyl-β-D-mannopyranosylamine and halopurines revealed that Pd-catalyzed conditions. It was also shown that thermal anomerization of the N-glycosides easily occurred, which resulted in the predominant formation of the β-anomer as the thermodynamically favored compound, and the activation energy of anomerization of 15 was estimated to be ca. 30 kcal/mol. The novel aminoheptose unit of spicamycin was prepared stereoselectively by carbon elongation of an acyclic aldehyde, prepared by ring cleavage reaction of a highly functionalized cyclohexane derived from naturally abundant myo-inositol. The Pd-catalyzed coupling reaction of the β-heptopyranosylamine with protected 6-chloropurine, followed by deprotection, provided spicamycin amino nucleoside, whose condensation with dodecanoylglycine completed the total synthesis of I. This study confirmed the proposed unique structure of a novel nucleoside antibiotic.
IT 222296-26-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(total synthesis of spicamycin via Pd-catalyzed coupling, condensation, and thermal anomerization reactions)
RN 222296-26-6 CAPLUS
CN β-D-Mannopyranosylamine, N-[9-[(4-methoxyphenyl)methyl]-9H-purin-6-yl]-2,3,4,6-tetrakis-O-(phenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 74 THERE ARE 74 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2001:809683 CAPLUS
DN 136:70032
TI Synthesis of Novel Guanidinoglycoside: 2-Glycosylamino-4,5-dihydro-6-pyrimidinone
AU Lin, Peishan; Lee, Cheng Leng; Sim, Mui Mui
CS Institute of Molecular and Cell Biology, Singapore, 117609, Singapore
SO Journal of Organic Chemistry (2001), 66(24), 8243-8247
CODEN: JOCEAH; ISSN: 0022-3263
PB American Chemical Society
DT Journal
LA English
OS CASREACT 136:70032
GI



I

AB 2-Glycosylamino-4,5-dihydro-6-pyrimidinones, e.g. I, were prepared from β-glycosyl isothiocyanate via condensation with azides followed by cyclocondensation with amino acid Me esters.
IT 385433-15-8P 385433-17-0P 385433-31-8P
385433-32-9P 385433-33-0P 385433-34-1P
385433-35-2P 385433-36-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(synthesis guanidino glycoside glycosylaminodihydropyrimidinone from β-glycosyl isothiocyanate via condensation with azides followed by cyclocondensation with amino acid Me esters)
RN 385433-15-8 CAPLUS
CN Benzoic acid, 4-[[(4S)-tetrahydro-6-oxo-4-phenyl-2-[(2,3,4,6-tetra-O-acetyl-α-D-glucopyranosyl)imino]-1(2H)-pyrimidinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 385433-17-0 CAPLUS
CN Benzoic acid, 4-[[(4S)-tetrahydro-6-oxo-4-phenyl-2-[(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)imino]-1(2H)-pyrimidinyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 385433-31-8 CAPLUS
CN 1H-Isoindole-1,3(2H)-dione, 2-[2-[(4S)-5,6-dihydro-6-oxo-2-[(2,3,4,6-tetra-O-acetyl-α-D-glucopyranosyl)amino]-4-(2-thienylmethyl)-1(4H)-pyrimidinyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 385433-32-9 CAPLUS
CN 1H-Isoindole-1,3(2H)-dione, 2-[2-[(4S)-5,6-dihydro-6-oxo-2-[(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)amino]-4-(2-thienylmethyl)-1(4H)-pyrimidinyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 385433-33-0 CAPLUS
CN 4(3H)-Pyrimidinone, 3-[(4-chlorophenyl)methyl]-5,6-dihydro-2-[(2,3,4,6-tetra-O-acetyl-α-D-glucopyranosyl)amino]-6-(2-thienylmethyl)-, (6S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 385433-34-1 CAPLUS
CN 4(3H)-Pyrimidinone, 3-[(4-chlorophenyl)methyl]-5,6-dihydro-2-[(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)amino]-6-(2-thienylmethyl)-, (6S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 385433-35-2 CAPLUS
CN 4(3H)-Pyrimidinone, 3,6-bis[(4-chlorophenyl)methyl]-5,6-dihydro-2-[(2,3,4,6-tetra-O-acetyl-α-D-glucopyranosyl)amino]-, (6R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 385433-36-3 CAPLUS
CN 4(3H)-Pyrimidinone, 3,6-bis[(4-chlorophenyl)methyl]-5,6-dihydro-2-[(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)amino]-, (6R)- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1999:199467 CAPLUS
DN 130:267672
TI Pd-catalyzed coupling reaction of glycosylamines with 6-chloropurines: synthesis of 6-(β-D-mannopyranosylamino)-9H-purine and its β-D-gluco isomer, N-glycoside models for spicamycin and septacidin
AU Chida, Noritaka; Suzuki, Tamotsu; Tanaka, Sayaka; Yamada, Iwao
CS Department of Applied Chemistry, Faculty of Science and Technology, Keio University, Yokohama, 223-8522, Japan
SO Tetrahedron Letters (1999), 40(13), 2573-2576
CODEN: TELEAY; ISSN: 0040-4039
PB Elsevier Science Ltd.
DT Journal
LA English
AB The first example of preparation of 6-(β-D-mannopyranosylamino)-9H-purine, whose N-glycosidic linkage corresponds to a natural antibiotic, spicamycin, by Pd-catalyzed coupling reaction of a mannopyranosylamine with 9-protected-6-chloropurine, followed by deprotection, is described. Its β-D-gluco isomer was also synthesized. This work established the procedure to construct the novel N-glycoside, in which the pyranose unit is connected to the amino group at C(6) of adenine moiety.
IT 222296-26-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of (β-D-mannopyranosylamino)purine and its β-D-gluco isomer via Pd-catalyzed coupling reaction of glycosylamines with

chloropurines)
RN 222296-26-6 CAPLUS
CN β-D-Mannopyranosylamine, N-[9-[(4-methoxyphenyl)methyl]-9H-purin-6-yl]-2,3,4,6-tetrakis-O-(phenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1986:220261 CAPLUS
DN 104:220261
OREF 104:34813a,34816a
TI Metabolism of 4,4'-methylenebis(2-chloroaniline) by canine liver and kidney slices
AU Manis, Melanie O.; Braselton, W. Emmett, Jr.
CS Dep. Pharmacol. Toxicol., Michigan State Univ., Ann Arbor, MI, 48109, USA
SO Drug Metabolism and Disposition (1986), 14(2), 166-74
CODEN: DMDSAI; ISSN: 0090-9556
DT Journal
LA English
GI



I

AB 4,4'-Methylenebis(2-chloroaniline) (MBOCA)(I) [101-14-4] metabolism in canine liver and kidney slices was investigated using HPLC to sep. the metabolites. Liver slices metabolized 5-10% of the [14C]MBOCA in 60 min and produced 7 metabolites resolved by HPLC. The major metabolite, representing .apprx.80% of the metabolism, was 2-amino-5-[(4-amino-3-chlorophenyl)methyl]-3-chlorophenyl H sulfate [102411-04-1], previously identified as the major urinary metabolite in dogs. An O-glucuronide [102411-06-3] was characterized as labile to β-glucuronidase, stable to arylsulfatase, and mild acid. It was formed in increased amts. when 2,6-dichloro-4-nitrophenol (DCNP) was added to the incubation. Two other glucuronide metabolites were labile to mild acid and β-glucuronidase, stable to arylsulfatase, and were formed in decreased amts. in the presence of D-(+)-galactosamine (D-gal) and p-nitrophenyl sulfate (PNPS). Renal cortical slices metabolized 3-5% of the [14C]MBOCA in 90 min, producing 6 metabolites. Based on retention time and lability to hydrolysis, 3 of these, the MBOCA-glucoside, a glucuronide, and 2-amino-5-[(4-amino-3-chlorophenyl)methyl]-3-chlorophenyl H sulfate, were also found as kidney metabolites. One addnl. S-containing metabolite was labile to mild acid and arylsulfatase. The major kidney metabolite represented 25-40% of the metabolism and was unaffected by mild acid, β-glucuronidase, arylsulfatase, DCNP, anddD-gal. Covalent binding in liver slices was 20-27 pmol/mg of wet weight/60 min and in kidney was 9-13 pmol/mg of wet weight/90 min. Binding was not altered in either tissue by

D-gal, PNPS, or low concns. of DCNP. Renal medullary slice incubations produced no [14C]MBOCA metabolites observed by HPLC with UV absorbance or radioactivity monitoring. Tissue covalent binding was 1.2 pmol/mg/90 min and was unchanged by the addition of aspirin or indomethacin, but doubled with 1 mM arachidonic acid.

IT 102411-05-2
RL: BIOL (Biological study)
(as methylenebis(chloroaniline) metabolite, in kidney and liver)

RN 102411-05-2 CAPLUS

CN β-D-Glucopyranosylamine, N-[4-[(4-amino-3-chlorophenyl)methyl]-2-chlorophenyl]- (CA INDEX NAME)

Absolute stereochemistry.



L8 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1966:38688 CAPLUS

DN 64:38688

OREF 64:7229b-c

TI Chemotherapy of fascioliasis. IV. Action of aromatic amines against liver flukes. 2

AU Laemmler, G.; Loewe, H.

CS Farbwerke Hoechst A.-G., Frankfurt/M., Germany

SO Arzneimittel-Forschung (1962), 12, 164-8
From: CZ 1965(22), Abstr. 1680.
CODEN: ARZNAD; ISSN: 0004-4172

DT Journal

LA German

AB Of 209 aromatic and arylaliphatic mono- and bis-amino compds., 114 were chemotherapeutically effective on rabbits, sheep, and cattle infected with Fasciola hepatica. The partial occurrence of sight disturbances and blinding of treated sheep and cattle prohibited their use. Cf. ibid (1), 15-21; CA 51, 3839b.

IT 30796-64-6
(Derived from data in the 7th Collective Formula Index (1962-1966))

RN 30796-64-6 CAPLUS

CN D-Glucopyranosylamine, N,N'-(methylenedi-4,1-phenylene)bis- (CA INDEX NAME)

Absolute stereochemistry.



L8 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1966:38687 CAPLUS

DN 64:38687

OREF 64:7229a-b

TI Observation of curare-like activity in the alkaloids from Delphinium rugulosom

AU Mamedov, G. M.

SO Azerbaidzhanskii Meditsinskii Zhurnal (1965), 42(9), 31-4
CODEN: AZMZA6; ISSN: 0005-2523
DT Journal
LA Azerbaijani
AB cf. CA 63, 11922b. Two alkaloids with the empirical formula of C19H23NO4 and C21H31NO4 were isolated in 0.64% yield from the small wrinkled D. rugulosom. Pharmacol. investigation was performed with HBr and HI salts of the whole alkaloid extract and HCl salt of the individual alkaloids. The salts at 0.5-2.5 mg./kg., administered into a cat, manifested curate-like activity.
IT 30796-64-6
(Derived from data in the 7th Collective Formula Index (1962-1966))
RN 30796-64-6 CAPLUS
CN D-Glucopyranosylamine, N,N'-(methylenedi-4,1-phenylene)bis- (CA INDEX NAME)

Absolute stereochemistry.



L8 ANSWER 14 OF 14 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1961:70587 CAPLUS
DN 55:70587
OREF 55:13385b-c
TI Water-soluble, therapeutically active glucosides
IN Ruschig, Heinrich; Loewe, Heinz; Lammler, Georg
PA Farbwerke Hoechst AG
DT Patent
LA Unavailable
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 1075626		19600218	DE	

AB Compds., active against liver fluke disease in animals, are produced by the reaction of diaminodiphenyl compds. with mono- or oligosaccharides containing an aldehyde or ketone group, such as glucose, galactose, arabinose, fructose, sorbose, lactose, or substituted saccharides, in an organic solvent, such as aliphatic or cycloaliphatic alcs. or NO2 compds. The reaction proceeds at normal or elevated temperature and can be accelerated by the addition of NH4 or PH4 ions. The products possess high activity; 75 mg./kg. bis(p,p'-glucosidaminophenyl)methane effects complete eradication of liver flukes in sheep.
IT 30796-64-6
(Derived from data in the 6th Collective Formula Index (1957-1961))
RN 30796-64-6 CAPLUS
CN D-Glucopyranosylamine, N,N'-(methylenedi-4,1-phenylene)bis- (CA INDEX NAME)

Absolute stereochemistry.



IT 122596-75-2P, Galactosylamine, N,N'-(methylenedi-p-phenylene)-bis-
RL: PREP (Preparation)
(preparation of)
RN 122596-75-2 CAPLUS
CN Galactopyranosylamine, N,N'-(methylenedi-p-phenylene)bis-, D- (6CI) (CA INDEX NAME)

Absolute stereochemistry.